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Background. This paper aimed to assess the utility of second-line chemotherapy in patients with advanced soft-tissue sarcoma.
Materials and Methods. A retrospective search of a prospectively maintained database identiﬁed patients treated between 1991 and
2005. Patients with gastrointestinal stromal tumours, small round cell tumours, and Ewing’s sarcoma were excluded. Response
was assessed using WHO and RECIST. Patients who achieved stable disease for 6 months or more were classiﬁed as having disease
control. Results. Three hundred and seventy-nine patients received second-line chemotherapy. Eighty-six (22.7%) achieved disease
control. Median duration of response was 11 months (95% CI: 9–13). On multivariate analysis, pathological subtype, absence of
lung metastases, and the use of combination chemotherapy were independent predictors of disease control. Twenty-eight (16.1%)
patients who failed to respond to ﬁrst-line therapy achieved disease control. Eight (2.1%) patients had suﬃcient downstaging to
enablecompletesurgicalresection.Progression-freesurvivalwas23%at6months.Medianoverallsurvivalwas8months(95%CI:
7–10months).Onmultivariateanalysis,synovialhistologyandabsenceoflungmetastaseswereassociatedwithimprovedsurvival.
Conclusion. Second-line chemotherapy can provide clinical beneﬁt in over 20% of soft-tissue sarcoma patients.
1.Introduction
Soft-tissue sarcomas (STSs) are malignant tumors of con-
nective tissue that account for 1% of all human cancers
[1]. They consist of approximately 50 diﬀerent histological
subtypes and have diﬀering clinical behavior and response to
chemotherapy. The median age at diagnosis is 50 years.
Intheadvanceddiseasesetting(locallyadvanced,inoper-
ableormetastatic)palliativechemotherapyisthemainstayof
treatment [2], although in a small subset this treatment may
be curative [3]. Doxorubicin is, by consensus, the standard
ﬁrst line therapy [4]. Trabectedin has recently emerged as
an eﬀective agent in patients who have progressed on an
anthracycline and ifosfamide. Trofosfamide and gemcitabine
appear to be associated with some activity and tolerability in
the doxorubicin/ifosfamide refractory patients [5]. Taxanes,
such as paclitaxel have been reported to have activity in
vascular sarcomas [5, 6]. There is ongoing work on the
potential use of molecular targeted therapies such as antian-
giogenic agents, IGF1-R, HDAC, and mTOR inhibitors [7,
8]. There are also ongoing developments in establishing
biomarkers to allow further personalisation of therapy
[9].
Combination chemotherapy in our practice is largely
reservedforthosewithrapidlyprogressingmetastaticdisease
or inoperable soft tissue sarcoma where response may
render disease resectable. In a recent meta-analysis, three-
randomized phase III trials were identiﬁed comparing
combination chemotherapy regimens containing ifosfamide
with regimens without ifosfamide. This analysis revealed
that the addition of ifosfamide to a chemotherapy regimen
signiﬁcantly improved response rates but did not produce
a signiﬁcant diﬀerence in 1 year survival. Higher rates of
adverse events, including myelosuppression and death, were
observed in patients who received combination chemother-
apy [10].2 Sarcoma
A retrospective review, performed by the EORTC, of
2185 patients treated with ﬁrst-line anthracycline-based
regimens (within a number of clinical trials) demonstrated
an overall one-year survival of 48% and two-year survival
of 22%. Good performance status, young age, and absence
of liver metastases were associated with improved survival
and response to chemotherapy. The poor responsiveness
of patients with liver metastases may have been from the
inclusion of patients with GIST in older studies. Low
histopathological grade was associated with longer survival
but a lower response rate. Patients with liposarcoma and
synovial sarcoma had signiﬁcantly longer survival, and
those with malignant ﬁbrous histiocytoma had signiﬁcantly
shorter survival. A signiﬁcantly higher response rate was
observed in patients with liposarcoma and a lower response
rate in those with leiomyosarcoma [11]. Further review of
EORTC data looked speciﬁcally at pretreated patients. Pro-
gression,freesurvivalat3monthswas39%forthosepatients
receiving active agents and 21% for those receiving inactive
regimens [12]. At six months progression free survival was
14% for those patients receiving active agents and 8% for
those receiving inactive regimens. Three prognostic factors
were identiﬁed: treatment with an active drug, interval since
initial diagnosis, and performance status.
Ap r e v i o u ss t u d yc o n d u c t e da tT h eR o y a lM a r s d e n
Hospital retrospectively analyzed the eﬃcacy of ﬁrst-line
chemotherapy in a large unselected cohort of patients with
advanced STS [13]. The study by Karavasilis demonstrated
that approximately 50% of patients beneﬁted from ﬁrst-line
chemotherapy and that synovial sarcoma and liposarcoma
were associated with a better prognosis.
There are, however, no data on the beneﬁt of second-line
chemotherapy outside the context of a clinical trial. The aim
of this study therefore was to look at a sequential, unselected
group of patients being treated as part of routine clinical
care in the second-line setting, using the same cohort of
patients reported by Karavasilis. The aim was to assess the
true clinic beneﬁt derived from second-line chemotherapy
for this patient group outside the context of a clinical trial
and to delineate potential predictive and prognostic factors
in this setting.
2.MaterialsandMethods
Prior to commencing the study, approval was obtained from
The Royal Marsden Hospital Audit Committee. A retro-
spective search of the prospectively maintained The Royal
Marsden Hospital Sarcoma Unit database was performed
to identify patients registered between 1991 and 2005 who
had received second-line chemotherapy for advanced or
metastaticdisease.Adjuvantchemotherapywasnotclassiﬁed
as ﬁrst-line treatment. Those with osteosarcoma, Ewing’s
sarcoma, gastrointestinal stromal tumors, rhabdomyosar-
c o m a ,a n do t h e rs m a l lr o u n dc e l lt u m o r sw e r ee x c l u d e d .
The analysis only included patients treated with second-
line chemotherapy at The Royal Marsden Hospital. All
patientshadtheirhistologyreviewedonreferraltoTheRoyal
MarsdenHospital.Onlythosepatientswithadvanceddisease
(primary tumor or local recurrence not amenable to surgical
resection) or metastatic disease were included. Patients who
received adjuvant chemotherapy were only included if they
subsequently received palliative chemotherapy for recurrent
advanced disease.
The following variables were obtained from the database;
date of presentation, date of birth, sex, histological subtype,
status of disease (advanced/metastatic), sites of metastases
at time of second-line chemotherapy, date of second-line
chemotherapy, second-line chemotherapy used, and number
of cycles administered. Date of last follow-up or death was
obtained. The response to treatment was categorized as
stabledisease(SD),progressivedisease(PD),partialresponse
(PR), or complete response (CR). Response to treatment
was assessed from radiology reports using WHO or RECIST
criteria (more recent reports using RECIST). Duration of
response was measured from the ﬁrst documented radiolog-
ical evidence until the time of progression. Repeat radiology
was performed whilst on chemotherapy every 2 to 3 cycles
and whilst not on chemotherapy every 2 to 3 months.
Radiological assessment was with cross-sectional imaging or
chest radiography in those patients with assessable disease
withthismodality.Patientswereclassiﬁedashavingadisease
control if they had CR, PR, or SD for 6 months or more.
Use of this classiﬁcation of response, referred to as “disease
control rate” or “progression free rate”, has been proposed as
a valid response measurement in a number of tumour types
[12, 14].
3.StatisticalMethods
The following were investigated as potential predictive and/
or prognostic factors.
(i) Age at start of second-line chemotherapy (less than
40 years/40 to 59 years/over 60 years).
(ii) Gender.
(iii) Histology (e.g., leiomyosarcoma/synovial sarcoma/
liposarcoma).
(iv) Sites of disease at start of second-line chemo (liver,
lung, bone).
(v) Time from primary diagnosis to second-line chemo
(<1 year/1-2 years/>2y e a r s ) .
(vi) Type of second-line chemotherapy (single agent/
combination).
Overall survival was illustrated by means of Kaplan-
Meier curves and diﬀerences between groups were assessed
using univariate analysis by the log-rank test. A multivariate
analysis was done to determine the independent signiﬁcance
of variables using the proportional hazards model.
Theresponseratewasexpressedasapercentagewith95%
conﬁdence interval.
The inﬂuence of prognostic variables on response rate
was assessed in a univariate analysis by means of the chi-
squared test, Fishers exact test, or the t-test and in a
multivariate analysis by means of binary logistic regression.Sarcoma 3
Table 1: Clinical characteristics.
Patients 379
Sex Male:Female 176:203
Age at 2nd-Line chemo (years) Median (Range) 50 (18–81)
Histology
Leiomyosarcoma 134 (35.4%)
Synovial sarcoma 52 (13.7%)
Liposarcoma 39(10.3%)
Other: 154 (40.6%)
Malignant Fibrous Histiocytoma 25
Sarcoma (not otherwise speciﬁed) 30
Fibrosarcoma 9
Malignant Peripheral nerve sheath tumour 12
Angiosarcoma 18
Other 60
Disease
Advanced 40 (10.6%)
Metastatic—single organ 186 (49.1%)
Metastatic—multiple organs 153 (40.4%)
Sites of metastases
Lung 231 (60.9%)
Liver 73 (19.3%)
Bone 23 (6.1%)
Table 2: Second-line chemotherapy regimens and disease control
rate.
Chemotherapy
Single agent doxorubicin 62 (16.4%)
Single agent ifosfamide 123 (32.5%)
Other Single agent 106 (28.0%)
Doxorubicin/ifosfamide 21 (5.5%)
Other combination 32 (8.4%)
Phase I trial 35 (9.2%)
Number of Cycles 123 4 5 6 >6
72 111 35 49 16 68 28
Response
CR 8 (2.1%)
PR 20 (5.3%)
SD 76 (20.1%)
PD 266 (70.2%)
NA 9 (2.4%)
Disease control rate CR/PR/SD >6 months 86 (23.2%)
Non responder 284 (76.8%)
CR: complete response, PR: partial response, SD: stable disease, PD: pro-
gressive disease, NA: not assessable.
All signiﬁcance tests were 2-sided and a 5% level of
signiﬁcance was used; no adjustment was made for multiple
testing.
4. Results
4.1. Demographics. Between January 1991 and December
2005, 687 new patients were registered at The Royal Marsden
Hospital with locally advanced or metastatic STS. Four
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Figure 1: Duration of disease control.
hundredandthirtythreereceivedsecond-linechemotherapy.
Fifty-four patients were excluded from the analysis; 52
were reviewed at The Royal Marsden Hospital but received
second-line chemotherapy at other institutions and 2 were
paediatric patients. A total of 379 patients were considered
eligible for analysis (176 males and 203 females). The most
common histological subtype was leiomyosarcoma (35.4%)
followed by synovial (13.7%) and liposarcoma (10.3%). At
the start of second-line treatment 40 patients had locally
advanced disease (10.6%) and 339 (89.4%) had metastatic
disease. Lung was the most common site of metastases
(60.9%), followed by liver (19.3%) and bone (6.1%). One
hundred and ﬁfty three had metastases in multiple organs
(40.4%) (Table 1).4 Sarcoma
Table 3: Response to second-line chemotherapy according to pathology and regime.
Histology Chemo CR PR SD PD NA
Synovial
Dox 1 (0.3%) 3 (0.8%) 1 (0.3%)
Ifos 1 (0.3%) 4 (1.1%) 2 (0.5%) 15 (4.0%) 1 (0.3%)
Dox/Ifos 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%)
Other 2 (0.5%) 4 (1.1%) 13 (3.4%)
Liposarcoma
Dox 1 (0.3%) 1 (0.3%) 3 (0.8%) 2 (0.5%)
Ifos 2 (0.5%) 3 (0.8%) 14 (3.7%)
Dox/Ifos 5 (1.3%) 1 (0.3%)
Other 1 (0.3%) 5 (1.3%) 6 (1.6%)
Leiomyosarcoma
Dox 1 (0.3%) 7 (1.8%) 12 (3.2%) 1 (0.3%)
Ifos 1 (0.3%) 4 (1.1%) 27 (7.1%) 2 (0.5%)
Dox/Ifos 1 (0.3%) 2 (0.5%)
Other 2 (0.5%) 14 (3.7%) 59 (15.6%)
Other:
Dox 6 (1.6%) 23 (6.1%)
Ifos 1 (0.3%) 2 (0.5%) 11 (2.9%) 31 (8.2%) 2 (0.5%)
Dox/Ifos 6 (1.6%)
Other 2 (0.5%) 2 (0.5%) 11 (2.9%) 50 (13.2%) 2 (0.5%)
Dox: doxorubicin, Ifos: Ifosfamide, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not assessable.
4.2. Response to Chemotherapy. Three hundred and twenty
six (86.0%) patients were treated with single-agent chemo-
therapy. Of these 62 received single-agent doxorubicin
(19.0%) and 123 (37.7%) single-agent ifosfamide. Thirty-
ﬁve (10.7%) were treated with a single agent within various
Phase 1 trials. One hundred and six patients (28%) received
anothersingleagent.Forty-oneofthesereceivedtrabectedin,
other regimens included infusional or oral etoposide, pacli-
taxel, dacarbazine, and gemcitabine. Three patients (0.9%)
who had endocrine therapy were also included in the single
agent chemotherapy group. Fifty-three patients had combi-
nationchemotherapy,21withanifosfamideanddoxorubicin
combination. A median of 3 cycles of chemotherapy were
given, with a range of 1 to 24. No other therapy was given for
advanced disease other than pulmonary metastastectomy.
Disease control was deﬁned as CR, PR, or SD of 6
months, or more. If a patient had a CR or PR less than 6
months they were still classiﬁed as having achieved disease
control(thiswasthecasein7patientswithaPR).Thosewith
SD for 6 months or more were classiﬁed as being progression
free for over six months and included in the disease control
rate group for analysis. The duration was measured from the
ﬁrstradiological documentation of response. Disease control
was seen in 86 (22.7% of patients). Of these 8 (9.3%) had a
complete response, 20 (23.3%) had a partial response and
58 (67.4%) had stable disease for 6 months or more. Of
the 42 patients receiving trabectedin 12 (28.6%) achieved
disease control. Of the 18 patients receiving gemcitabine and
docetaxelincombination4(22.2%)achieveddiseasecontrol.
Nine (2.4%) of patients were lost to follow up before any
radiological assessment was performed and were therefore
judged as not assessable (Tables 2 and 3).
Of those patients who achieved disease control, the
duration of control was 11 months (95% CI: 9–13 months).
(Figure 1) For patients who achieved stable disease as their
best response, the median duration of disease stabilization
was 6 months. Fifty-eight of these patients had disease
stabilization for 6 months or more.
On univariate analysis, liposarcoma patients had better
disease control to second-line chemotherapy than other
histologicalsubtypes(P = .03).Patientswithlungmetastases
were less likely to achieve disease control (P = .04). Patients
were more likely to achieve disease control to combination
chemotherapy than to single agent chemotherapy (P = .02)
(Table 4).
Patients who responded (achieved disease control) to
ﬁrst-line chemotherapy were marginally more likely to
respond to second-line chemotherapy though this did not
reach statistical signiﬁcance (P = .06, Fishers exact test)
(Table 5).
On multivariate logistic regression analysis, pathological
subtype and lung metastases were independent predic-
tors of disease control to treatment. After adjusting for
pathology and lung metastases, patients having combination
chemotherapy had a better disease control rate (P = .01)
(Table 4).
4.3. Survival Analysis. Progression-free survival was 23% at
sixmonths,11%atoneyear,and4%attwoyears.Atthetime
of analysis 65 patients were alive. Median survival from start
of second-line chemotherapy was 8 months (95% CI: 7–10).
Thirty six percent of patients were alive at one year and 4%
at 5 years (Figure 2).
On univariate analysis, older patients had signiﬁcantly
worse survival (P = .03) and those with synovial histology
had signiﬁcantly better survival (P = .008) (Table 6).
On multivariate analysis, synovial histology (P = .005)
and lack of lung involvement (P = .01) were signiﬁcant
independent factors associated with improved overall sur-
vival. After adjusting for histology and lung disease, patientsSarcoma 5
Table 4: Univariate and multivariate analysis of disease control rate.
Univariate analysis
Disease control rate
All Patients 23.2% (95% CI:18.9%–27.5%)
Sex Male 24% P =.6
Female 22%
Age (years)
0–39 24% P =.2
40–59 27%
60+ 16%
Histology
Leiomyosarcoma 19% P = .2
Synovial sarcoma 34% P =.07
Liposarcoma 38% P = .03
Other 19%
Disease
Locally advanced 18% P =.1
Metastatic—single organ 29%
Metastatic—multiple organs 17%
Sites of metastases
Involved versus uninvolved
Lung 19% versus 29% P = .04
Liver 27% versus 22% P =.4
Bone 23% versus 23% P = 1.0
Chemotherapy Single agent/Phase I 21% P =.02
Combination 36%
Chemo Regimen
SA Doxorubicin 27%
SA Ifosfamide 21%
Other SA 22%
Phase I trial 9%
Dox/Ifos combination 38%
Other combination 34%
Multivariate analysis
Relative likelihood of disease control (95% CI) Signiﬁcance
Pathology type
Liposarcoma versus other 2.5 1.2–5.1 P = .02
Synovial versus other 2.3 1.2–4.5 P =.02
Sites of disease
Lungs Involved 0.6 0.3–1.0 P = .04 Not involved 1.0
Chemotherapy
Single Agent/Phase 1 Combination 1.0 1.2–4.4 P = .01 2.3
SA: single agent, Dox/ Ifos: Doxorubicin/Ifosfamide.
Table 5: Disease control rate of ﬁrst-line chemotherapy against
disease control rate of second-line chemotherapy.
1st-line chemotherapy
Responder Non responder
2nd-line chemotherapy Responder 42 28
Non responder 130 145
on combination chemotherapy had better prognosis than
those treated with a single agent (P = .004) in the second-
line setting (Table 6).
5. Discussion
The role of second-line chemotherapy in metastatic STS is
not well established. The aim of our study was to assess
response and survival in an unselected cohort of patients
with advanced STS treated with second-line chemotherapy
at a single centre so providing a reﬂection of the true
beneﬁt derived from second-line chemotherapy in routine
practice. Such a study is limited by the availability of
retrospectively gathered data and our data do not include
primary tumour site or histological grading. However all
our patients had advanced progressive disease at the time of
treatment so histological grading of the original tumour is
of less relevance as a prognostic factor. Patient performance
status was also not documented consistently. However,
in our clinical practice all patients must have a WHO
performance status of 0 to 2 to receive chemotherapy.
The study also used a cohort of patients being treated
largely in the era before subtype speciﬁc therapy for
soft tissue sarcoma was practiced so current practice may
diﬀer slightly from that practiced in the earlier part of
the cohort.6 Sarcoma
Table 6: Univariate analysis (Life table & Logrank) and multivariate analysis (Cox regression) of survival.
Univariate analysis
Median Survival (months) Signiﬁcance
Sex Male 8 P = .4
Female 9
Age
0–39 9 P = .03
40–59 9
60+ 7
Histology
Leiomyosarcoma 9
Synovial versus the rest P = .008 Synovial 12
Liposarcoma 11
Other 7
Disease
Locally Advanced 8 P = .3
Metastatic—single organ 9
Metastatic—multiple organs 8
Sites of metastases
Involved versus uninvolved
Lung 7 versus 10 P = .2
Liver 8 versus 8 P = .5
Bone 12 versus 8 P = .7
Multivariate analysis
Relative risk 95% CI Signiﬁcance
Histology
Synovial 0.6 0.5–0.9 P = .005
Other histology 1.0
Site
Not involved 1.0 1.1–1.7 P = .01
Involved 1.4
Chemotherapy
Combination 0.6 0.4–0.9 P = .004
Single agent/Phase I 1.0
In our cohort of 379 pretreated patients, 86.0% received
single-agent chemotherapy, compared to 61% of patients
in our report of ﬁrst-line therapy [13]. The higher use
of combination chemotherapy in the ﬁrst-line setting is
consistent with the use of more toxic combination regimens
in potentially resectable disease. Response has been shown
to be higher with combination chemotherapy, though with
more toxicity [10]. In our study, patients treated with
combinationregimens(36%)hadsigniﬁcantlyhigherdisease
control rates than those treated with single-agents (21%).
This may be due to the selection of ﬁtter patients for
combination chemotherapy. Performance status was not
consistently documented in the database and so this impor-
tant factor could not be included in the analyses. However,
nosigniﬁcantdiﬀerenceinmedianagewasobservedbetween
those on combination chemotherapy versus single-agent,
hencetherewasnoobviousagebiasinselectionoftreatment.
Therefore, where tumour shrinkage is the primary goal of
treatment or in the case of rapidly progressing disease the
use of combination chemotherapy in the second-line setting
appears justiﬁed.
Patients who respond to ﬁrst-line chemotherapy were
also marginally more likely to respond to second-line
chemotherapy, though this did not reach statistical signiﬁ-
cance.
The fact that 19% of patients received doxorubicin
second-line can be explained by the fact that some patients
would have been treated in the context of clinical trials,
such as a study comparing ifosfamide with doxorubicin
as ﬁrst-line therapy [15]. Patients with liposarcoma had
signiﬁcantly better response to second-line chemotherapy,
and this is consistent with ﬁrst-line chemotherapy data [11,
13]. Of the 39 liposarcomas, 25 (64.1%) were classiﬁed as
myxoid/round cell. This tumour subtype has been shown to
have better response rates to ﬁrst-line chemotherapy [16].
The EORTC study also suggested that the absence of liver
metastases was associated with a signiﬁcantly better response
tochemotherapy.Incontrast,ourstudysuggeststhatpatientsSarcoma 7
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Figure 2: Overall survival.
with lung metastases were signiﬁcantly less likely to respond
to chemotherapy. However, our analyses were performed
by multiple lines of testing, and consequently it is not
possible to draw deﬁnite conclusions regarding the associ-
ation between metastatic site and response to second-line
chemotherapy.
Median overall survival in our patients was 8 months,
one-year survival 36% and ﬁve-year survival only 4%. This is
consistent with previous studies estimating median survival
to be between 7 and 12 months from commencing ﬁrst-
line chemotherapy [5]. Furthermore, one-year survival has
been documented as 48% and ﬁve-year survival as 8% in
patients treated with ﬁrst-line chemotherapy [11, 13]. In
our study, younger age, synovial histology, and absence of
lung metastases were associated with signiﬁcantly longer
survival. Synovial histology has previously been found to be
an independent prognostic factor in patients treated with
ﬁrst-line chemotherapy [11, 13].
Survivalcanbelongterminasmallsubsetofpatientsand
an EORTC study has demonstrated that complete remission
can occur in all histological subtypes. This was more likely to
occur in those who achieved a complete response to ﬁrst-line
chemotherapy [3]. Eight patients in our cohort (2.1%) had
suﬃcient downstaging following second-line chemotherapy
to allow surgical resection of residual disease. Four of these
patients had synovial sarcoma.
In conclusion, our study has shown that more than
20% of soft tissue sarcoma patients treated with second-
line chemotherapy can obtain prolonged beneﬁt for over 6
months. In addition, conﬁrmed responses were observed in
a small proportion of patients who did not respond to ﬁrst-
line chemotherapy. Those with liposarcoma, absence of lung
metastases, and patients treated with combination regimens
were signiﬁcantly more likely to respond to second-line
therapy. The median duration of response or stable disease
was 11 months and in a small subset of patients complete
remission was achieved with multimodality management.
Our study conﬁrms the diﬀerential response of histological
subtypes to chemotherapy and the need to select patients for
second-line treatment carefully according to those who are
more likely to derive clinical beneﬁt. There remains a need
for novel eﬀective therapies in metastatic STS, particularly
for patients with certain chemoresistant subtypes, who
currently have a poor prognosis.
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